详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.

10| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]he Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province Hospital of Chinese Medical, Guangzhou, China [2]Department of Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China [3]Department of Oncology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China [4]International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden

出处：

DOI：

ISSN：

关键词： Glioblastoma Anlotinib Leptomeningeal spread

摘要：

Glioblastoma (GBM) is the most common and the most aggressive primary malignant brain tumor in adults. Although tumor recurrence is inevitable, leptomeningeal spread is relatively rare. We describe a case of leptomeningeal spread recurrent GBM treated with anlotinib in this report. When the recurrent GBM patient had leptomeningeal spread was administered anlotinib 10mg p.o. once every day and added oral temozolomide chemotherapy 100mg/m2 (days 1-7, days 15-21, 28-day cycle) after 3 months. The patient's overall survival time was more than 5 months and developed oral ulcer and acute cerebral infarction during his oral administration of anlotinib. This patient showed a favorable clinic outcome for treatment of leptomeningeal spread recurrent GBM with anlotinib and didn't show serious side effects.Copyright © 2021 Elsevier B.V. All rights reserved.

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版中科院分区表Review为是的期刊

：

大类 | 3 区医学

小类 | 4 区神经科学

最新[2025]版：

无

JCR分区：

出版当年[2019]版：

Q4 NEUROSCIENCES

最新[2023]版：

无

影响因子： 0 最新[2023版] 0 最新五年平均 1.746 出版当年[2019版] 3.061 出版当年五年平均 2.961 出版前一年[2018版] 2.453 出版后一年[2020版]

第一作者：

第一作者机构： [1]he Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province Hospital of Chinese Medical, Guangzhou, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC [2]Current Immunotherapies for Glioblastoma Multiforme. [3]Current Immunotherapies for Glioblastoma Multiforme. [4]MicroRNA-378 enhances inhibitory effect of curcumin on glioblastoma. [5]Novel Therapeutic Advances in Glioblastoma Preface [6]PD-1 Combined with VEGF/VEGFR2 Inhibitors for the Re-Treatment of Metastatic Nasopharyngeal Carcinoma [7]Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer [8]Synthesis and anti-glioblastoma effects of artemisinin-isothiocyanate derivatives [9]Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006) a multicentre, open-label, single-arm, phase 2 trial [10]Suppression of the USP10/CCND1 axis induces glioblastoma cell apoptosis.